CellProthera, BioCardia Report Success From Collaborative Phase II Trial Of ProtheraCytes For Acute Myocardial Infarction; Plan To Continue Relationship Into Phase III

7/8/24 7:05:47 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $BCDA alert in real time by email

CellProthera's clinical results from the Phase I/IIb EXCELLENT Trial, which studied the feasibility of transendocardial injection of ProtheraCytes for acute myocardial infarction when delivered in combination with the standard of care, suggested an effective solution for preventing heart failure progression in the patients at high risk following a heart attack.

Get the next $BCDA alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$BCDA

Date	Price Target	Rating	Analyst
12/20/2021	$9.00	Buy	HC Wainwright & Co.

More analyst ratings

BioCardia to Host Q3 2024 Corporate Update and Financial Results Conference Call on November 13, 2024
SUNNYVALE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the three and nine months ended September 30, 2024 by conference call on Wednesday, November 13, 2024 at 4:30 PM ET. Following management's formal remarks, there will be a question-and-answer session. Participants can register for the conference by navigating to https://dpregister.com/sreg/10194429/fdf5f0e427. Please note that registered participants will receive their dial-in number upon registration.
11/6/24 7:00:00 AM ET
$BCDA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
BioCardia Completes Phase III Randomized Double-Blind Controlled Trial of Autologous Cell Therapy for Ischemic Heart Failure
SUNNYVALE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today the completion of its last protocol specified follow-up visit in CardiAMP HF, a prospective, randomized, double-blinded, placebo procedure controlled, multi-center pivotal clinical trial for the treatment of heart failure of reduced ejection fraction (HFrEF). The CardiAMP HF Trial is assessing the safety and effectiveness of the CardiAMP® Cell Therapy System for HFrEF, with the potential to reduce all cause death, future hospitalizations, enhance functional capacity, as well
10/28/24 9:00:00 AM ET
$BCDA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
BioCardia Regains Full Compliance with Nasdaq Listing Requirements
SUNNYVALE, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today that the Company has regained full compliance with the Nasdaq Capital Market's Listing Requirements as required by the Hearing Panel's (the "Panel") decision on May 13, 2024. On September 17, 2024, BioCardia received notice from Nasdaq confirming that the Company has demonstrated compliance with Listing Rule 5550(b)(1) (the "Equity Rule") of The Nasdaq Stock Market. Accordingly, the Panel has determined to continue the listing of the Company's securities on the Nasdaq Stock
9/18/24 8:30:00 AM ET
$BCDA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

$BCDA
Financials

Live finance-specific insights

BioCardia to Host Q3 2024 Corporate Update and Financial Results Conference Call on November 13, 2024
SUNNYVALE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the three and nine months ended September 30, 2024 by conference call on Wednesday, November 13, 2024 at 4:30 PM ET. Following management's formal remarks, there will be a question-and-answer session. Participants can register for the conference by navigating to https://dpregister.com/sreg/10194429/fdf5f0e427. Please note that registered participants will receive their dial-in number upon registration.
11/6/24 7:00:00 AM ET
$BCDA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results
SUNNYVALE, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the second quarter of 2024 and filed its quarterly report on Form 10-Q for the three and six months ended June 30, 2024 with the Securities and Exchange Commission. The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights. Following management's formal remarks, there will be a question-and-answer session. Recent Business Highlights BCDA-01: CardiAMP® autologous cell therapy in ischemic heart failure of re
8/13/24 4:30:00 PM ET
$BCDA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
BioCardia to Host Q2 2024 Corporate Update and Financial Results Conference Call on August 13, 2024
SUNNYVALE, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the three months ended June 30, 2024 by conference call on Tuesday, August 13, 2024 at 4:30 PM ET. Following management's formal remarks, there will be a question-and-answer session. Participants can register for the conference by navigating to https://dpregister.com/sreg/10191562/fd3d36338a. Please note that registered participants will receive their dial-in number upon registration. For those who have not
8/7/24 7:00:00 AM ET
$BCDA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

CellProthera, BioCardia Report Success From Collaborative Phase II Trial Of ProtheraCytes For Acute Myocardial Infarction; Plan To Continue Relationship Into Phase III

Chat with this insight

Recent Analyst Ratings for $BCDA

$BCDA Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by BioCardia Inc.

SEC Form SC 13D/A filed by BioCardia Inc. (Amendment)

SEC Form SC 13D/A filed by BioCardia Inc. (Amendment)

$BCDA Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

President and CEO Altman Peter bought $1,513 worth of shares (500 units at $3.03), increasing direct ownership by 1% to 39,745 units (SEC Form 4)

President and CEO Altman Peter bought $1,645 worth of shares (500 units at $3.29), increasing direct ownership by 1% to 39,245 units (SEC Form 4)

President and CEO Altman Peter bought $1,760 worth of shares (500 units at $3.52), increasing direct ownership by 1% to 38,745 units (SEC Form 4)

$BCDA Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

$BCDA SEC Filings

$BCDA Press Releases

Fastest customizable press release news feed in the world

HC Wainwright & Co. initiated coverage on BioCardia with a new price target

BioCardia downgraded by Dawson James

BioCardia Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

BioCardia Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

BioCardia Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

BioCardia to Host Q3 2024 Corporate Update and Financial Results Conference Call on November 13, 2024

BioCardia Completes Phase III Randomized Double-Blind Controlled Trial of Autologous Cell Therapy for Ischemic Heart Failure

BioCardia Regains Full Compliance with Nasdaq Listing Requirements

$BCDA Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Senior Vice President, Devices Gillis Edward M gave a grant of 15,808 shares and covered exercise/tax liability with 6,840 shares, decreasing direct ownership by 65% to 12,225 units (SEC Form 4)

President and CEO Altman Peter was granted 44,250 shares and covered exercise/tax liability with 21,680 shares, increasing direct ownership by 28% to 103,981 units (SEC Form 4)

Chief Financial Officer Mcclung David was granted 24,193 shares and covered exercise/tax liability with 11,565 shares, increasing direct ownership by 73% to 30,008 units (SEC Form 4)

$BCDA Financials

Live finance-specific insights

BioCardia to Host Q3 2024 Corporate Update and Financial Results Conference Call on November 13, 2024

BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results

BioCardia to Host Q2 2024 Corporate Update and Financial Results Conference Call on August 13, 2024

$BCDA Market Insights

Live Market Insights

BioCardia Secures New Patent For Innovative Heart Procedure Technology

BioCardia Has Been Granted U.S. Patent Number 12,036,371 Titled "Method of accessing the left atrium with a multi-directional steerable catheter"